Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...

EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.

Masimo (Nasdaq: MASI) + Masimo Corporation $172.4 1.44% Open 173.198 Day High 175.067 52 Week High 147.89 52 Week Low 75.22 announced today that it appointed Katie Szyman as its new CEO, effective Feb ...

The acquisition of Critical Care assets from Edwards Lifesciences (NYSE:EW), completed in late 2024, has been a significant development for BD. This strategic move is expected to contribute positively ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

The discontinued operations includes critical care, as well as a small, non-core product group that reduces the reported sales of surgical structural heart. Edward Lifesciences reports in three ...

IRVINE, Calif., September 03, 2024--Edwards Lifesciences (NYSE: EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX) for $4.2 ...